Leva Pelvic Health System Provides Enhanced Care with New Educational Content
Mayo Clinic is one of the most trusted names in healthcare – and integrating their educational expertise into our Leva System enhances our ability to serve patients with clinically grounded and evidence-based resources they can trust.
The content expands the Leva app's existing educational resources on UI, now including additional information on the types of UI, tips on controlling urgency, understanding constipation and ways to manage it, and healthy bladder frequently asked questions (FAQs). Leva users can access the content directly while completing their 12-week at-home therapy program. As part of the collaboration, Axena Health expects to provide additional Mayo Clinic educational content to Leva users over time.
'This is an exciting step forward in our mission to redefine the standard of care for women's pelvic health,' said Randy Pritchard, CEO of Axena Health. 'Mayo Clinic is one of the most trusted names in healthcare – and integrating their educational expertise into our Leva System enhances our ability to serve patients with clinically grounded and evidence-based resources they can trust. We are grateful for their support and ongoing collaboration to deliver better patient outcomes.'
Education is a core component of Axena Health's approach to treating UI. The Leva System is designed to provide women with a convenient, non-invasive option for UI treatment through a modern approach to supervised pelvic floor muscle training. The physician-prescribed program uniquely combines the FDA-cleared Leva device and smartphone app to provide at-home guided treatment, personalized coaching, educational resources, and progress tracking.
'A critical part of our Leva therapy is ensuring women feel educated and supported during their treatment,' added Dr. Mandy Pulliam, Chief Medical Officer of Axena Health. 'By enhancing our existing educational resources in the Leva app with Mayo Clinic's content, we are empowering women to better understand their condition and actively engage in their care.'
For more information about the Leva Pelvic Health System, visit www.levacares.com.
About Axena Health
Axena Health, Inc. is dedicated to improving the lives of women with pelvic floor disorders. Axena Health's flagship product, the Leva ® Pelvic Health System, offers a novel, effective, first-line treatment for urinary incontinence (UI) and chronic fecal incontinence (FI), underreported conditions affecting over 78 million and 12 million women in the U.S. alone. Axena Health's technology enables a modern approach to supervised pelvic floor muscle training via precise visualization of movement in real time, while monitoring usage and progress. For more information, please visit www.axenahealth.com or www.levacares.com and follow Axena Health on LinkedIn.
About the Leva ® Pelvic Health System
The Leva ® Pelvic Health System offers an innovative, non-invasive, medication-free way for women to treat urinary incontinence (UI) and chronic fecal incontinence (FI) — at home in just five minutes a day. Combining a small FDA-cleared vaginal motion sensor with integrated software, the Leva System offers precise, real-time visualization of pelvic movement, progress tracking and active physician involvement, all of which support improved treatment outcomes. The Leva System is available by prescription only, enabling physician engagement in each patient's success while also offering scalable first-line treatment of UI and chronic FI. The Leva System has multiple clinical trials and published data from globally recognized medical centers supporting its efficacy in treating UI, including two studies in Obstetrics and Gynecology (The Green Journal), the official publication of the American College of Obstetricians and Gynecologists (ACOG).
Important Indication and Other Information for the Leva ® Pelvic Health System
The Leva ® Pelvic Health System is intended for (1) strengthening of pelvic floor muscles, (2) rehabilitation and training of weak pelvic floor muscles for the treatment of stress, mixed, and mild to moderate urgency urinary incontinence (including overactive bladder) in women and (3) rehabilitation and training of weak pelvic floor muscles for the first-line treatment of chronic fecal incontinence (>3-month uncontrolled passage of feces) in women. Treatment with the Leva System is by prescription and is not for everyone. Please talk to your prescriber to see if Leva System is right for you. Your prescriber should discuss all potential benefits and risks with you. Do not use Leva System while pregnant, or if you think you may be pregnant, unless authorized by your doctor. For a complete summary of the risks and instructions for the Leva System, see its Instructions for Use available at www.levacares.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's (NASDAQ:INSM) Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older. Brinsupri is the first and only FDA-approved treatment for NCFB, a chronic lung condition characterized by permanently widened and damaged airways (bronchi), leading to persistent mucus production, recurrent infections, and difficulty breathing. There are approximately 500,000 people in the U.S. diagnosed with NCFB. The approval is based on data from the Phase 3 ASPEN and Phase 2 WILLOW ASPEN, patients taking Brinsupri 10 mg or 25 mg had a 21.1% and 19.4% reduction in the annual rate of exacerbations, respectively, as compared to placebo. Both dosage strengths of Brinsupri also met several exacerbation-related secondary endpoints, including significantly prolonging the time to first exacerbation and significantly increasing the proportion of patients remaining exacerbation-free over the treatment period. Patients who received Brinsupri 25 mg experienced a statistically significantly less decline in lung function, as measured by forced expiratory volume in one second (FEV₁) after using a bronchodilator, at week 52. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions in WILLOW. In parallel, applications for brensocatib with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have been accepted, and the company plans to file in Japan in 2025. Commercial launches are anticipated in 2026, pending approval in each territory. Price Action: INSM stock is up 6.20% at $119.89 at the last check on Tuesday. Read Next:Photo: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? INSMED (INSM): Free Stock Analysis Report This article FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
24 minutes ago
- CNBC
FDA may pull authorization of Pfizer's Covid vaccine for children under 5
The Food and Drug Administration is weighing revoking its authorization of Pfizer's Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC on Tuesday. The move could leave many kids with no available shot against the virus, as jabs from Moderna and Novavax are cleared for more limited populations. While Covid typically causes mild symptoms in most children, others, such as infants under 1 or those with certain health conditions, can be at a higher risk of severe illness and hospitalization. If the FDA pulls the authorization, it would add to a string of recent efforts by U.S. health agencies to change and undermine immunization policy since Health and Human Services Secretary Robert F. Kennedy Jr. — a prominent vaccine skeptic — took the helm. HHS did not immediately respond to a request for comment. The FDA told Pfizer it might not renew its longstanding emergency use authorization for children aged 6 months to 4 years, the company said in a statement. Pfizer said it has requested the authorization to remain in place for the upcoming fall and winter season and is "currently in discussions with the agency on potential paths forward." The company said that the FDA's "deliberations" are not related to the safety and efficacy of the shot, "which continues to demonstrate a favorable profile." The Guardian first reported on the FDA's potential move. Moderna is working with the Centers for Disease Control and Prevention to boost supplies of its own Covid shot for children, the Guardian reported on Saturday. In July, the FDA granted full approval to Moderna's Covid vaccine for children — but only for those with health conditions that may put them at increased risk of severe illness if they become infected. Both shots from Moderna and Pfizer user messenger RNA technology. Kennedy has targeted those vaccines in the past, filing a petition in May 2021 demanding that the agency revoke authorization of the jabs. Meanwhile, Novavax's protein-based shot has never been available for children under 12. In May, Kennedy announced that the Centers for Disease Control and Prevention has removed its recommendation of Covid vaccines for healthy children and pregnant women. But in updated guidance days later, the CDC said the shots "may" be given to those kids if a doctor agreed that it was necessary. Covid vaccines during pregnancy are now listed as "No Guidance/Not Applicable," where they were previously recommended for all pregnant adults.
Business Upturn
26 minutes ago
- Business Upturn
Mellow Sleep Redefines Comfort with a Revolutionary New Cloud Pillow
Dover, Aug. 12, 2025 (GLOBE NEWSWIRE) — DOVER, DE – August 11, 2025 – Mellow Sleep, a leader in sleep ergonomics and material science, today announced the launch of a revolutionary new cloud pillow designed to permanently solve the universal problem of restless, unfulfilling sleep. This launch marks a new era for sleep wellness, moving beyond one-size-fits-all solutions to offer a truly personalized and restorative experience. The frustrating, nightly search for a pillow that is 'just right' is finally over. Millions of people struggle with pillows that are too firm, too soft, too high, or too low, leading to neck pain, shoulder stiffness, and persistent fatigue. This nightly battle for comfort often involves folding, bunching, or stacking pillows in a desperate attempt to find support. Mellow Sleep addresses this issue at its core with a groundbreaking cloud pillow that intelligently adapts to the sleeper. This innovative pillow solves sleep discomfort through its proprietary 3-zone contour design. Each zone is meticulously engineered for a distinct biomechanical purpose. The central contour cradles the head with gentle, pressure-relieving support, while the raised outer edges are optimized for side sleepers, filling the gap between the shoulder and neck. The third zone provides a specialized cervical ramp that delivers a targeted lift, ensuring the spine maintains a natural and healthy alignment throughout the night. This integrated system prevents the awkward angles that lead to morning aches and pains. 'Our goal was to create the perfect cloud pillow by listening to the real-world frustrations of sleepers,' said Jay Yue, founder of Mellow Sleep. 'People are tired of compromising. They shouldn't have to choose between a soft feel and firm support. We spent years researching materials and ergonomics to find a way to deliver both. The result is our new CloudAlign™ Pillow, a product we believe sets a new industry standard for what a pillow can and should do for your well-being. It's more than just a place to rest your head; it's an investment in your health.' At the heart of this exceptional Mellow Sleep cloud pillow is the CloudSoft Core™, a proprietary shape-retaining memory foam. Unlike conventional foams that can be slow to respond or lose shape, the CloudSoft Core™ offers dynamic, flexible support that adapts instantly to every micro-movement. This ensures consistent comfort and alignment, whether you are a back, side, or combination sleeper. The exterior is just as thoughtfully designed. The pillow is encased in a removable, OEKO-TEX® Certified cover. This certification guarantees the fabric is free from harmful chemicals, making it hypoallergenic, breathable, and exceptionally gentle on the skin. Further enhancing its superior adaptability, the pillow features a SwitchFit™ design. This innovative feature gives users dual-height support, allowing them to simply flip the pillow to choose between a lower and a higher profile to perfectly match their body frame and sleep preference. For lasting hygiene, all materials are fast-drying and easily washable. This new Mellow Sleep cloud pillow from Mellow Sleep is now available for purchase directly from the company's website: offering an end to compromise and a new beginning for deep, restorative sleep. About Mellow Sleep: Mellow Sleep is a forward-thinking company dedicated to advancing human well-being through the science of sleep. By focusing on biomechanics, certified non-toxic materials, and user-centric design, Mellow Sleep creates innovative products that provide tangible improvements to sleep health. Their mission is to engineer a better night's sleep for a better life. Media Contact: [email protected] ### For more information about Mellow LLC, contact the company here: Mellow LLCJay Yue9293555134 [email protected] 8 The Green, Dover, DE 19901
